Defining the pharmacology, safety, and dosing of ?PB-FC? a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

• Forschungsstelle: INNOSUISSE
• Projektnummer: 120.452 IP-LS
• Projekttitel Englisch: Defining the pharmacology, safety, and dosing of ?PB-FC? a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Schlüsselwörter (Englisch)

Life sciences, Pharmaceuticals

Abstract (Englisch)

In this project PharmaBiome?s Functional Consortium (PB-FC) designed for the treatment of gut dysbiosis in acute graft-versus-host disease (aGvHD) patients will be tested in mouse models to answer essential questions for the successful translation of our novel, function-based approach.